149 related articles for article (PubMed ID: 27028809)
1. [Hormone Resistance and Neuroendocrine Differentiation Due to Accumulation of Genetic Lesions during Clonal Evolution of Prostate Cancer].
Mikhaylenko DS; Efremov GD; Sivkov AV; Zaletaev DV
Mol Biol (Mosk); 2016; 50(1):34-43. PubMed ID: 27028809
[TBL] [Abstract][Full Text] [Related]
2. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line.
Marcias G; Erdmann E; Lapouge G; Siebert C; Barthélémy P; Duclos B; Bergerat JP; Céraline J; Kurtz JE
Hum Mutat; 2010 Jan; 31(1):74-80. PubMed ID: 19830810
[TBL] [Abstract][Full Text] [Related]
4. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
Nguyen MM; Wang Z
Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
6. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.
Shiota M; Yokomizo A; Naito S
Free Radic Biol Med; 2011 Oct; 51(7):1320-8. PubMed ID: 21820046
[TBL] [Abstract][Full Text] [Related]
7. Hormone treatment for prostate cancer: current issues and future directions.
Ichikawa T; Suzuki H; Ueda T; Komiya A; Imamoto T; Kojima S
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():58-63. PubMed ID: 16273367
[TBL] [Abstract][Full Text] [Related]
8. The androgen receptor: genetic considerations in the development and treatment of prostate cancer.
Cude KJ; Dixon SC; Guo Y; Lisella J; Figg WD
J Mol Med (Berl); 1999 May; 77(5):419-26. PubMed ID: 10426191
[TBL] [Abstract][Full Text] [Related]
9. [The mechanisms of prostate cancer progression through androgen receptor].
Goto Y; Sakamoto S; Ichikawa T
Nihon Rinsho; 2016 Jan; 74(1):55-9. PubMed ID: 26793880
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment.
Marques RB; Erkens-Schulze S; de Ridder CM; Hermans KG; Waltering K; Visakorpi T; Trapman J; Romijn JC; van Weerden WM; Jenster G
Int J Cancer; 2005 Nov; 117(2):221-9. PubMed ID: 15900601
[TBL] [Abstract][Full Text] [Related]
11. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor plasticity and its implications for prostate cancer therapy.
Snow O; Lallous N; Singh K; Lack N; Rennie P; Cherkasov A
Cancer Treat Rev; 2019 Dec; 81():101871. PubMed ID: 31698174
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
14. Androgen axis in prostate cancer.
Culig Z; Bartsch G
J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathogenesis and progression of prostate cancer.
Schrecengost R; Knudsen KE
Semin Oncol; 2013 Jun; 40(3):244-58. PubMed ID: 23806491
[TBL] [Abstract][Full Text] [Related]
16. Cancer stem cell and mesenchymal cell cooperative actions in metastasis progression and hormone resistance in prostate cancer: Potential role of androgen and gonadotropin‑releasing hormone receptors (Review).
Contreras HR; López-Moncada F; Castellón EA
Int J Oncol; 2020 May; 56(5):1075-1082. PubMed ID: 32319606
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications.
Deng Q; Tang DG
Endocr Relat Cancer; 2015 Dec; 22(6):T209-20. PubMed ID: 26285606
[TBL] [Abstract][Full Text] [Related]
18. Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets.
Mellado B; Marin Aguilera M; Pereira MV
Arch Esp Urol; 2013 Jun; 66(5):453-62. PubMed ID: 23793763
[TBL] [Abstract][Full Text] [Related]
19. Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer.
Mitsiades CS; Koutsilieris M
Expert Opin Investig Drugs; 2001 Jun; 10(6):1099-115. PubMed ID: 11772238
[TBL] [Abstract][Full Text] [Related]
20. Collocation of androgen receptor gene mutations in prostate cancer.
Buchanan G; Greenberg NM; Scher HI; Harris JM; Marshall VR; Tilley WD
Clin Cancer Res; 2001 May; 7(5):1273-81. PubMed ID: 11350894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
